BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced that WPS Government Health Administrators, ...

Diagnosing lung diseases is easier than it used to be with a new state-of-the-art pulmonary function machine recently installed at St. Luke's Hospital. A Vmax Series product from Sensor Medics is a ...

Biodesix, Inc. announced a new study published in CHEST Pulmonary Journal reaffirming the effectiveness of its Nodify CDT® blood-based lung nodule test, which assesses seven autoantibodies linked to ...

One of the largest studies to investigate whether Preserved Ratio Impaired Spirometry (PRISm), an understudied low lung function state, is an early predictor of co-morbidities has found it is strongly ...

LOUISVILLE, Colo., May 15, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (BDSX) (Nasdaq: BDSX), a leading diagnostic solutions company, announced that new data will be presented at the International Society ...

This release is also available in Chinese on EurekAlert! Chinese. In the two largest clinical studies ever conducted on the molecular genetics of lung cancer, an international team led by scientists ...

A new study led by researchers at Johns Hopkins Kimmel Cancer Center is showing a novel blood test can detect the presence of lung cancer with over 90 percent accuracy. The test uses artificial ...

Five blood-based lung tests are commercially available with Medicare coverage, focused on nodule-risk decisioning and treatment guidance, and the company is expanding from pulmonology into primary ...